Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
중증 COVID-19에 대한 JAK1/2 억제제 룩소리티닙의 동정적 사용: 전향적 관찰 연구
Clinical Trial
[키워드] 95% confidence interval
activated
adverse event
age
Anemia
anti-inflammatory properties
clinical
Clinical improvement
Comorbidities
Comorbidity
compassionate-use
compassionate-use protocol
contribute
Controlled clinical trial
controlled clinical trials
COVID-19
cumulative incidence
cytokine
defined
discharge home
distress
Efficacy
exposure time
FiO2
high-flow oxygen support
improvement
Infectious diseases
Inflammatory cytokine
inflammatory cytokine profile
inflammatory reaction
inhibitor
JAK1
JAK1/JAK2 inhibitor
JAK2
less
lymphocyte
Lymphocyte subset
median age
median dose intensity
not affected
observational study
Ordinal Scale
overall survival
oxygen
oxygen saturation
PaO2
paO2/fiO2
PaO2/FiO2 ratio
Patient
patients with COVID-19
prospective cohort
prospective observational study
pulmonary disease
Pulmonary function
pulmonary infiltrate
pulmonary infiltrates
respiratory distress
ruxolitinib
Safe
severe COVID-19
severe pulmonary disease
Therapeutics
thrombocytopenia
urinary tract infections
[DOI] 10.1038/s41375-020-01018-y PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1038/s41375-020-01018-y PMC 바로가기 [Article Type] Clinical Trial